Ignite Creation Date:
2024-05-06 @ 9:23 AM
Last Modification Date:
2024-10-26 @ 12:13 PM
Study NCT ID:
NCT02964988
Status:
TERMINATED
Last Update Posted:
2019-10-15
First Post:
2016-11-14
Brief Title:
uPAR PETCT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
Sponsor:
Rigshospitalet Denmark
Organization:
Rigshospitalet Denmark
Study Overview
Official Title:
uPAR PETCT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
Status:
TERMINATED
Status Verified Date:
2019-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Recruitment issues and interim results
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate the applicability of urokinase plasminogen activator receptor uPAR Positron Emission Tomography PET CT molecular imaging in patients with metastatic castration-resistant prostate cancer mCRPC
Detailed Description:
68Ga-NOTA-AE105 is a radioligand targeting urokinase plasminogen activator receptor uPAR which is a promising imaging biomarker of tumor aggressiveness 68Ga-NOTA-AE105 PETCT will be applied in patients with mCRPC during treatment with Radium-223 PETCT will be performed before initiation of Radium therapy and after two treatment cycles The initial semiquantitative uptake standard uptake values SUVs of 68Ga-NOTA-AE105 in metastases as well as the change in these parameters after therapy will be correlated with overall survival and progression free survival
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2016-002184-34 | EUDRACT_NUMBER | None | None |